PharmAla Biotech Holdings, Inc. (TSE:MDMA)
:MDMA
Top Page
PharmAla Biotech Holdings, Inc.
(MDMA)
Select Model
Select Model
Rating:49Neutral
Price Target:
C$0.10
▼(-13.64% Downside)
Action:ReiteratedDate:01/09/26
The score is held back primarily by weak financial performance: deteriorating profitability, negative gross profit, and ongoing cash burn despite improving revenue. Technicals are mixed with only modest near-term strength, and valuation is constrained by losses (negative P/E) with no dividend support.
Positive Factors
Regulated MDMA supply focus
PharmAla’s explicit focus on GMP‑compliant MDMA for clinical trials and potential prescription markets creates a durable, specialized business model. Being positioned as a regulated supplier can secure long‑term contracts with trial sponsors and future prescribers, raising barriers to entry and supporting predictable demand as mental health therapeutics commercialize.
Negative Factors
Negative gross profit and large losses
Negative gross profit signals that current production or direct costs exceed revenue, a structural issue that cannot be fixed by cutting SG&A alone. Large operating and net losses erode capital and indicate the core product economics are currently unviable, requiring meaningful cost restructuring or higher pricing to reach sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulated MDMA supply focus
PharmAla’s explicit focus on GMP‑compliant MDMA for clinical trials and potential prescription markets creates a durable, specialized business model. Being positioned as a regulated supplier can secure long‑term contracts with trial sponsors and future prescribers, raising barriers to entry and supporting predictable demand as mental health therapeutics commercialize.
Read all positive factors
PharmAla Biotech Holdings, Inc. (MDMA) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$10.89M
Dividend YieldN/A
Average Volume (3M)208.17K
Price to Earnings (P/E)―
Beta (1Y)0.95
Revenue Growth-72.51%
EPS Growth-170.13%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding108,887,215
10 Day Avg. Volume94,242
30 Day Avg. Volume208,173
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)5.47
Price to Sales (P/S)22.20
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PharmAla Biotech Holdings, Inc. Business Overview & Revenue Model
Company Description
Pharmala Biotech Holdings Inc., doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients. It also provides MDXX class compounds...
How the Company Makes Money
PharmAla Biotech Holdings, Inc. generates revenue through the development and sale of MDMA-based pharmaceutical products. The company conducts extensive research and clinical trials to ensure the efficacy and safety of its products, which are then...
PharmAla Biotech Holdings, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Aug 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 605.50K | 1.04M | 532.00K | 78.07K | 0.00 |
| Gross Profit | -845.17K | 887.44K | 454.10K | 75.78K | -303.00 |
| EBITDA | -2.07M | -573.36K | -710.18K | -973.45K | -2.51M |
| Net Income | -2.18M | -823.60K | -779.81K | -985.58K | -2.51M |
Balance Sheet | |||||
| Total Assets | 3.42M | 2.90M | 2.41M | 2.33M | 2.79M |
| Cash, Cash Equivalents and Short-Term Investments | 960.66K | 419.38K | 195.04K | 852.14K | 2.47M |
| Total Debt | 0.00 | 0.00 | 253.54K | 0.00 | 0.00 |
| Total Liabilities | 961.73K | 916.88K | 1.03M | 423.78K | 138.48K |
| Stockholders Equity | 2.46M | 1.98M | 1.38M | 1.91M | 2.66M |
Cash Flow | |||||
| Free Cash Flow | -1.05M | -547.78K | -846.39K | -1.62M | -435.76K |
| Operating Cash Flow | -1.04M | -321.36K | -339.66K | -625.37K | -173.57K |
| Investing Cash Flow | -935.27K | -226.42K | -506.74K | -994.87K | 629.22K |
| Financing Cash Flow | 1.60M | 772.12K | 189.29K | 0.00 | 2.02M |
PharmAla Biotech Holdings, Inc. Technical Analysis
Negative
0.11
Price Trends
0.10
Negative
0.11
Negative
0.11
Negative
Market Momentum
>-0.01
Positive
46.41
Neutral
30.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MDMA, the sentiment is Negative. The current price of 0.11 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.10, and above the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.41 is Neutral, neither overbought nor oversold. The STOCH value of 30.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MDMA.
PharmAla Biotech Holdings, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | C$10.89M | -6.26 | -78.88% | ― | -72.51% | -170.13% | |
48 Neutral | C$6.09M | -0.13 | 123.88% | ― | ― | 90.81% | |
42 Neutral | C$11.74M | -5.25 | 21.59% | ― | ― | -120.00% | |
42 Neutral | C$5.92M | -10.53 | -112.32% | ― | ― | 27.35% |
* Healthcare Sector Average
TSE:MDMA
PharmAla Biotech Holdings, Inc.
0.10
-0.07
-41.18%
TSE:CSCI
COSCIENS Biopharma
2.83
-1.18
-29.43%
TSE:APS
Aptose Biosciences
2.39
-0.60
-19.97%
TSE:SBM.H
Sirona Biochem
0.06
0.00
0.00%
TSE:PREV
PreveCeutical Medical
0.02
-0.02
-42.86%
TSE:PHRM
PharmaTher Holdings Ltd
0.07
-0.13
-65.79%
PharmAla Biotech Holdings, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Cortexa Deepens Lead in Australia’s MDMA Market With New GMP Supply and Expanded Access
Positive
Mar 23, 2026
Cortexa, a 50/50 joint venture between PharmAla Biotech and Vitura Health, has reinforced its leadership in Australia’s emerging psychedelic medicines market by commercializing the country’s first large‑scale GMP batch of MDMA ca...
Business Operations and Strategy
PharmAla Expands MDMA Trial Footprint With Nautilus Sanctuary Data Deal
Positive
Mar 3, 2026
PharmAla Biotech has signed a Supply Data Agreement with Nautilus Sanctuary in New York to provide its LaNeo MDMA for a Phase 2 open-label clinical trial using MDMA-assisted therapy to treat post-traumatic stress and adjustment disorders in front...
Business Operations and Strategy
PharmAla Donates MDMA for Fibromyalgia Trial in Major U.S. Research Collaboration
Positive
Feb 26, 2026
PharmAla Biotech has signed a drug donation agreement with Spaulding Rehabilitation, part of the Mass General Brigham system, to supply its LaNeo MDMA at no cost for a clinical trial investigating MDMA-assisted therapy in fibromyalgia patients. In...
Business Operations and StrategyProduct-Related Announcements
PharmAla Strikes Amsterdam UMC Supply Deal to Advance Commercial-Grade MDMA Packaging
Positive
Feb 23, 2026
PharmAla Biotech Holdings has signed a binding supply agreement with Amsterdam University Medical Center in the Netherlands to provide LaNeo 40 mg MDMA capsules for a proposed clinical trial. The product will be repackaged into a new single-capsul...
Business Operations and StrategyExecutive/Board Changes
PharmAla Biotech Reshapes Board With Addition of Veteran Financial Executive
Positive
Feb 10, 2026
PharmAla Biotech Holdings Inc., a specialist in MDMA and MDXX-class psychedelic molecules, develops and manufactures clinical-grade compounds for research and patient treatments while advancing proprietary candidates such as its lead asset ALA-002...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.